Hormone and Nonhormone Therapy for the Maintenance of Postmenopausal Health: The Need for Randomized Controlled Trials of Estrogen and Raloxifene

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

1996 • 7,450 citations

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women

1998 • 6,250 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Design of the Women’s Health Initiative Clinical Trial and Observational Study

1998 • 2,456 citations

Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

1992 • 2,379 citations

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1997 • 1,641 citations

A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men

1998 • 1,142 citations

Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer

1992 • 1,139 citations

Hormone replacement therapy and endometrial cancer risk: A meta-analysis

1995 • 944 citations

Estrogen Therapy in Postmenopausal Women

1998 • 927 citations

Risk of venous thromboembolism in users of hormone replacement therapy

1996 • 827 citations

Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

1992 • 824 citations

Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women

1998 • 702 citations

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

1994 • 614 citations

Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens

1996 • 606 citations

Perspectives: How many women have osteoporosis now?

1995 • 603 citations

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1995 • 602 citations

HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS

1998 • 597 citations

Prospective study of exogenous hormones and risk of pulmonary embolism in women

1996 • 580 citations

Postmenopausal Bone Loss Is Prevented by Treatment with Low-Dosage Estrogen with Calcium

1987 • 531 citations

Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis

1987 • 477 citations

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1997 • 450 citations

A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

1996 • 362 citations

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

1996 • 285 citations

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial

1995 • 284 citations

Heart and Estrogen/progestin Replacement Study (HERS)

1998 • 251 citations

Postmenopausal Hormone Use and Risk of Large-Bowel Cancer

1995 • 235 citations

Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI

1996 • 190 citations

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group

1997 • 186 citations

Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women The Scottish Heart Health Study

1998 • 159 citations

Coronary Heart Disease Mortality and Adjuvant Tamoxifen Therapy

1997 • 156 citations

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.

1994 • 152 citations

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

1997 • 149 citations

Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits

1997 • 135 citations

Coronary heart disease: an older woman's major health risk

1997 • 133 citations

In Search of Optimal Long-Term Female Hormone Replacement: The Potential of Selective Estrogen Receptor Modulators

1997 • 130 citations

Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients

1990 • 94 citations

Increased risk of cholecystectomy in users of supplemental estrogen

1988 • 86 citations

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

1996 • 86 citations

Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer

1993 • 84 citations

Effect of Tamoxifen on Measurements of Hemostasis in Healthy Women

1996 • 81 citations

Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta.

1997 • 78 citations

Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.

1996 • 68 citations

Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.

1997 • 58 citations

Overview of Estrogen Replacement Therapy: A Historical Perspective

1998 • 55 citations

The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women

1995 • 50 citations

Estrogens, Progestins, and Heart Disease

1998 • 46 citations

POSTMENOPAUSAL HORMONE THERAPY

1998 • 18 citations